Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues

Esperion Therapeutics, Inc. (ESPR) incurred a loss per share of 50 cents in the fourth quarter of 2023, narrower than the Zacks Consensus Estimate of a loss of 53 cents. The company incurred a loss of 76 cents per share in the year-ago quarter.Esperion generated revenues of $32.3 million, up 72% year over year. The reported figure beat the Zacks Consensus Estimate of $26.8 million.Quarter in DetailEsperion has two FDA-approved drugs in its commercial portfolio — Nexletol and Nexlizet — that are approved for ...